Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Constitutive activation of phosphoinositide 3-kinase (PI3K) is common in human cancers.
• Small-cell lung cancer (SCLC) has a poor prognosis, necessitating novel targeted therapies.
• PI3K pathway dysregulation, via PIK3CA mutation or PTEN loss, is implicated in SCLC tumorigenesis.

Purpose of the Study:

• To evaluate the efficacy of the selective PI3K inhibitor PF-4989216 in preclinical SCLC models.
• To determine if targeting the PI3K pathway is a viable therapeutic strategy for SCLCs with PIK3CA mutations.
• To investigate the differential effects of PF-4989216 in SCLC models with PIK3CA mutations versus PTEN loss.

Main Methods:

• In vitro assays assessed PI3K signaling, cell viability, apoptosis, cell-cycle progression, and transformation in SCLC cell lines treated with PF-4989216.
• In vivo studies evaluated pharmacokinetic/pharmacodynamic relationships and tumor growth inhibition (TGI) in sensitive SCLC xenografts.
• Cell lines with PIK3CA mutations or PTEN loss were utilized to explore differential responses.

Main Results:

• PF-4989216 effectively inhibited PI3K signaling, induced apoptosis, and reduced cell viability and tumor growth in SCLCs with PIK3CA mutations.
• In SCLCs with PTEN loss, PF-4989216 inhibited PI3K signaling but did not affect apoptosis, cell viability, or transformation.
• Differential mechanisms of tumorigenesis and apoptosis were observed between PIK3CA-mutated and PTEN-loss SCLC models.

Conclusions:

• PF-4989216 demonstrates potential as a targeted therapy for SCLC patients with PIK3CA mutations.
• The drug's efficacy is specific to PIK3CA-mutated SCLCs, with no observed benefit in PTEN-loss models.
• These findings highlight the importance of molecular profiling for guiding SCLC treatment strategies.